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Ying Liu1†, Wei Zhang1†, Xiao-Jie Wang2 and Shi Liu3*Abstract
Background: Kanglaite® injection (KLT), with a main ingredient of Coix seed oil (a traditional Chinese medicine),
has been widely used for cancer treatment in China. KLT has an inhibitory effect on many kinds of tumors and
PI3K/Akt/mTOR signaling promotes cell survival, proliferation, and progression in cancer cells. Therefore, targeting
this pathway may lead to the development of novel therapeutic approaches for human cancers.
Methods: Here, we examined the effects of KLT on the PI3K/Akt/mTOR pathway in pancreatic cancer xenografts in
mice, and assessed its therapeutic potential. Growth and apoptosis of tumor xenografts were examined, and the
expression levels of genes and proteins involved in the PI3K/Akt/mTOR pathway were measured by RT-PCR and
western blotting, respectively.
Results: Our results revealed that KLT dramatically inhibited the growth of pancreatic cancer xenografts and induced
apoptosis simultaneously. Furthermore, it downregulated the expression of phospho-Akt and phospho-mTOR.
Conclusions: These results suggest that KLT can suppress growth and induce apoptosis of pancreatic cancer
xenografts. Moreover, KLT can downregulate the expression of phospho-Akt and phospho-mTOR to modulate the
PI3K/Akt/mTOR signaling pathway.
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Pancreatic cancer is one of the most aggressive and
treatment-refractory cancers, and its 5-year survival rate is
less than 5% [1]. Therefore, effective new medicines are
urgently required to achieve greater survival of pancreatic
cancer patients. In recent years, traditional Chinese medi-
cine has been widely used in China as adjuvant treatment
during chemo- and radiotherapy for cancer [2]. Coix seed
is a Chinese herbal medicine that is used in the treatment
of hypertension, arthritis, cancer metastasis, asthma, and
immunological disorders [3]. The main ingredient of
Kanglaite® injection (KLT) is Coix seed oil [4], and it has
been widely used for cancer treatment in China [5].
Preclinical studies have found that KLT may block the
tumor cell cycle at the G2/M phase, and induce tumor
cell apoptosis by up-regulating the expression of Fas/
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reproduction in any medium, provided the orCOX-2 [2-8]. KLT is mainly used for the treatment of
non-small-cell lung cancer, liver cancer, and gastric can-
cer [2,5,9]. KLT has been found to significantly decrease
cancer cachexy, improve quality of life of cancer patients,
and may ameliorate multiple drug resistance of cancers
when combined with radiotherapy and chemotherapy in
clinical use [3,4].
Molecular targeting therapy against defined signaling
pathways has recently attracted much attention. PI3K/
Akt/mTOR is a pro-survival signaling pathway, and reg-
ulates cellular functions such as proliferation, differenti-
ation, and migration [10]. Dysregulation of this pathway
has been implicated in several cancers [11], including
human pancreatic cancer. Activated PI3K/Akt/mTOR
signaling impedes tumor cell apoptosis, promotes pro-
liferation, angiogenesis, invasion, and metastasis [12].
While KLT alone cannot cure lethal human malig-
nancies such as pancreatic cancer, there are no previous
findings on the effect of KLT on the PI3K/Akt/mTOR
pathway in treating pancreatic cancer. Therefore, we stu-
died the anti-cancer effect of KLT on the PI3K/Akt/This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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present study, nude mice with human pancreatic cancer
were treated with different concentrations of KLT and
the resulting changes in the tumor growth inhibition
rate, apoptosis, and protein expression levels of PI3K/
Akt/mTOR pathway components were measured to ex-
plore the therapeutic mechanism of KLT in pancreatic
cancer.Methods
Cell culture
The human pancreatic cancer cell line PANC-1 was ob-
tained from the Shanghai Institute of Biochemistry and
Cell Biology, Chinese Academy of Sciences (Shanghai,
China). Cells were cultured at 37°C in a 5% CO2 and 95%
air humidified atmosphere in RPMI 1640 (Gibco, USA)
supplemented with 10% fetal bovine serum (Hyclone,
USA) and 1% penicillin-streptomycin.Animals and pancreatic cancer model
Male BALB/c nude mice aged 6–8 weeks (weighing
18–22 g) were purchased from the Shanghai Experimen-
tal Animal Center (Shanghai, China) and KLT was pur-
chased from Zhejiang Kanglaite Pharmaceutical Co., Ltd
(Hangzhou, China). The mice were kept in autoclaved
cages with polyester fiber filters to avoid contact with
the pathogens in a 12-h light/12-h dark cycle at 22–25°C
and a humidity of 50–70%. Mice were fed with standard
laboratory food and water. A subcutaneous injection of
5 × 106 pancreatic cancer PANC-1 cells suspended in
0.1 mL phosphate buffered saline (PBS) was adminis-
tered in the right flank of each mouse, allowing for the
development of subcutaneous tumors after 10 days. Fol-
lowing tumor formation, mice (n = 40) were randomly
divided into four groups of 10 each: a control group; and
KLT 6.25, 12.5, and 25 mL/kg groups. Starting on the
11th day, mice in the KLT-treated groups were injected
daily with KLT intraperitoneally for 21 days. Mice in the
control group were injected with 0.9% normal saline.
The body weights of mice and tumor volumes were also
measured every 3 days. Tumor volumes were calcula-
ted with the formula: tumor volume (mm3) =maximal
length ×maximal width2/2 [13]. Mortality was also mon-
itored daily. After harvesting, tumors were weighed and
the tumor growth inhibition rate was calculated using
the formula: (mean tumor weight of control group −
mean tumor weight of treatment group)/mean tumor
weight of control group × 100% [14]. The 40 tumors
from the four groups were sliced into three parts for
examination. All animal experiments were approved by
the Animal Use and Management Committee of Qiqihar
Medical University.TUNEL assays
Terminal deoxynucleotidyl transferase-mediated dUTP
nick end labeling (TUNEL) assay was used to study DNA
fragmentation using the in situ cell death detection kit
(Roche Diagnostics, Germany) according to the manufac-
turer’s instructions [15]. Briefly, 40 xenograft tumor slices
were fixed in 4% paraformaldehyde, embedded in paraffin,
and cut into 6-μm sections. Sections of tumor tissue were
treated for 20 min with Proteinase K (20 μg/mL in PBS),
equilibrated for 10 min with TdT buffer, and incubated
for 2 h in the TdT mix containing 100 U TdT and
0.5 μL Biotin-16-dUTP. Biotin-16-dUTP labeled in
3-OH of DNA was detected by streptavidin-HRP and
visualized using diaminobenzidine for color reaction accor-
ding to the manufacturer’s instructions. TUNEL-positive
cells were counted in 10 randomly selected 400× high-
power fields under an Olympus microscope (Olympus Inc.,
Japan). The apoptotic index was calculated as: the number
of apoptotic cells/total number of nucleated cells × 100%.
RT-PCR analysis
Human PI3K, Akt, and mTOR mRNA expression was eval-
uated by RT-PCR as described previously [16]. GAPDH
served as the internal control. In brief, 40 tumor specimens
(100–150 mg each) from each group were washed in PBS
and minced into small pieces using bistouries. Then, sam-
ples were suspended in 1 mL of cold homogenizing buffer
and homogenized in an ice-cold grinder. Total RNA was
isolated from homogenate using TRIzol (Invitrogen, USA).
RT-PCR was performed using the AccessQuick RT-PCR
System (Promega, USA) according to the manufacturer’s
instructions. The primer sets were as follows: PI3K, 5′-
AGG AGC GGT ACA GCA AAG AA-3′ and 5′-GCC
GAA CAC CTT TTT GAG TC-3′; Akt, 5′-TGA AAA
CCT TCT GTG GGA CC-3′ and 5′-TGG TCC TGG
TTG TAG AAG GG-3′; mTOR, 5′-CTG GGA CTC
AAA TGT GTG CAG TTC-3′ and 5′-GAA CAA TAG
GGT GAA TGA TCC GGG-3′; GAPDH, 5′-GGA AGG
TGA AGG TCG GAG T-3′; and 5′-CCT GGA AGA
TGG TGA TGG G-3′. Thirty cycles of amplification were
performed under the following conditions: denaturation at
94°C for 30 s, annealing at 58°C (59°C for PI3K and 56°C
for mTOR) for 30 s, and extension at 72°C for 1 min. The
PCR products were analyzed by electrophoresis on a 2%
agarose gel, and image analysis was performed using NIH
Image software (Scion, USA). The experiments were re-
peated three times.
Western blotting
Protein extraction and western blotting analysis of tu-
mor cells were performed as described previously [14].
Briefly, 40 tumor specimens (100–150 mg each) from
each group were washed in PBS and minced into small
pieces using bistouries. Tissue samples were suspended
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in an ice-cold grinder. Then, the homogenate was centri-
fuged at 12,000 g for 15 min at 4°C. The supernatants
were used immediately or stored at −20°C. Then, the
protein concentrations were determined using a bicincho-
ninic acid protein assay kit (Pierce, USA). Equal amount
of protein was separated by 15% SDS-PAGE at 80 V for
1.5 h and transferred onto polyvinylidene difluoride mem-
branes (Millipore, USA) at 100 V for 2.5 h. After incuba-
tion in blocking solution (PBS with 10% non-fat dry milk
and 0.05% Tween-20) for 1 h at room temperature,
the membranes were incubated with a primary anti-
body (rabbit anti-PI3K, rabbit anti-Akt, mouse anti-
pAkt, rabbit anti-mTOR, rabbit anti-p-mTOR, mouse
anti-β-actin; Cell Signaling, USA) at a dilution of 1:1000
in TBS-Tween-20 (TBST; Sigma, USA) overnight at 4°C.
Membranes were then incubated with secondary anti-
bodies (1:2000 dilution in TBST; Cell Signaling) con-
jugated with horseradish peroxidase. After washing, the
blots were developed using an enhanced chemilumines-
cence detection system (Amersham International, UK)Figure 1 Effect of KLT on pancreatic cancer xenograft growth. When t
control group and a KLT 6.25, 12.5, and 25 ml/kg group. The mice in the K
21 days and the mice in the control group were injected with 0.9% norma
significantly different during the treatment (P > 0.05). B, C, and D: On the d
KLT-treated groups were not different compared with the control group (P
KLT-treated groups showed considerably lower tumor volume and weightaccording to the manufacturer’s protocol. Relative protein
levels were corrected by employing β-actin as the internal
standard. Experiments were repeated three times.
Statistical analysis
Statistical analysis was performed using SPSS 18.0 soft-
ware. The data are expressed as mean ± SD. Difference
of parameter between two samples was compared using
Student’s t-test. Differences among three and more pa-
rameters were analyzed by one-way analysis of variance. A
value of P < 0.05 was considered as statistically significant.
Results
Effects of KLT on tumor growth
To determine whether KLT has an anti-tumor effect
in vivo, a pancreatic carcinoma model was established by
subcutaneously injecting PANC-1 cells into nude mice.
After treatment with KLT for 21 days, none of the mice
exhibited any physical discomfort, and the average body
weight of the mice in each group was not significantly
different (P > 0.05; Figure 1A). On the day before KLThe tumors initially formed, the mice were divided into four groups: a
LT-treated groups were intraperitoneally injected daily with KLT for
l saline. A. Average body weight of the mice in each group was not
ay before KLT treatment, the tumor volumes and weights in the
> 0.05). After treatment with KLT for 21 days, the 12.5 and 25 mL/kg
compared with those in the control group (*P < 0.05).
Figure 2 Effect of KLT on the apoptosis of tumor xenografts.
A. TUNEL assay of tumor xenograft tissue (magnification: ×400).
B. The apoptosis indexes in KLT-treated groups was significantly
higher than those in the control group (*P < 0.05).
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in the KLT 6.25 mL/kg group, 51.47 ± 9.68 mm3 in the
KLT 12.5 mL/kg group, and 53.44 ± 12.98 mm3 in the
KLT 25 mL/kg group. Tumor volumes were not differ-
ent compared with those in the control group (59.16 ±
17.32 mm3) (P > 0.05; Figure 1B). After treatment with
KLT for 21 days, KLT-treated mice had considerably
lower tumor volume and weight: 566.01 ± 256.04 mm3
(0.45 ± 0.21 g) in the KLT 6.25 ml/kg group, 193.58 ±
57.29 mm3 (0.16 ± 0.05 g) in the KLT 12.5 mL/kg group,
and 108.18 ± 52.33 mm3 (0.09 ± 0.04 g) in the KLT
25 mL/kg group, compared with their previous values.
The volumes and weights in the KLT 12.5 mL/kg and
25 mL/kg groups were significantly lower than those of
the control group at 720.48 ± 200.28 mm3 (0.58 ± 0.16 g;
P < 0.05; Figure 1B, 1C, and 1D).
Effect of KLT on tumor cell apoptosis
To determine whether KLT can effectively induce pan-
creatic cancer cell apoptosis in vivo, tumor sections were
analyzed by TUNEL assay. TUNEL assays showed evi-
dent in situ apoptosis in the 6.25, 12.5, and 25 mg/kg
KLT-treated groups (Figure 2A). The apoptosis indexes
in the KLT-treated groups were 9.16 ± 4.87%, 19.76 ±
8.44%, and 28.43 ± 10.59%, respectively, and were signifi-
cantly higher than those in the control group at 2.75 ±
2.14% (P < 0.05; Figure 2B).
Effect of KLT on the expression of components involved
in the PI3K/Akt/mTOR pathway
The modulating effect of KLT on PI3K, Akt, and mTOR
mRNA expression is shown in Figure 3A and 3B. GAPDH
mRNA expression levels in KLT-treated groups were no
different than those in the control group (P > 0.05). The
expression levels of PI3K, Akt, and mTOR mRNA were
no different (P > 0.05) in the KLT-treated groups com-
pared with those in the control group after the mice were
treated with KLT for 21 days.
Next, we investigated the modulating effect of KLT on
the expression levels of PI3K, Akt, p-Akt, mTOR, and p-
mTOR (Figure 3C, 3D). After the mice were treated with
different concentrations of KLT for 21 days, the expression
levels of β-actin in the KLT-treated groups were no differ-
ent than those in the control group (P > 0.05). Expression
levels of pAkt and p-mTOR were significantly lower than
those in the control group after treatment (P < 0.05). The
expression levels of PI3K, Akt, and mTOR were no differ-
ent than those in the control group (P > 0.05).
Discussion
Our study was performed in nude mice bearing subcu-
taneous PANC-1 human pancreatic cancer xenografts.
The regression of tumor implants was measured in all
KLT-treated animals, and no overtly toxic effects or effectson weight gain were observed. Furthermore, decreased ex-
pression levels of pAkt and p-mTOR were detected in
KLT-treated tumors.
KLT has an inhibitory effect on many types of tumors
[7]. In our study, after treatment with KLT for 21 days,
the tumor volumes in KLT-treated groups were consid-
erably lower than those in the control group (P < 0.05).
The tumor inhibition ratios in the 25 and 12.5 mL/kg
groups were 84.48% and 72.41%, respectively, while the
6.25 mL/kg group was only 22.41% (P < 0.05). These data
illustrate that KLT contributed to the inhibition of tumor
growth in the xenograft animal model, which confirm
the findings of other researchers. Wu et al. found that
growth inhibition ratios in hepatoma xenografts were
46.4% and 49.4% after treatment with 5% and 10% KLT
Figure 3 Effect of KLT on the expression of components involved in the PI3K/Akt/mTOR pathway. A. After treatment with KLT for 21 days,
PI3K, Akt, and mTOR mRNA expression levels of tumor xenografts were examined by RT-PCR, and the PCR products were analyzed by electrophoresis
on a 2% agarose gel, followed an ethidium bromide stain. B. The expression levels of PI3K, Akt, and mTOR mRNA were unchanged (P > 0.05) in the
KLT-treated groups compared with the control group after treatment. C. After treatment with KLT for 21 days, PI3K, Akt, pAkt, mTOR, and p-mTOR
expression levels were detected by western blotting. D. After treatment with KLT for 21 days, the pAkt and p-mTOR expression levels were significantly
lower than those in the control group (*P < 0.05). The expression levels of PI3K, Akt, and mTOR were the same as those in the control group (P > 0.05).
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hibition ratios were 33.25% and 43.89% after lung cancer
xenografts were treated with 6.25 and 12.5 mL/kg of
KLT for 14 days [3]. Discrepancies in the experimental
methods used in these studies could explain the diversities
among these findings. The injection doses used in this
study are similar to those in other studies. The equivalent
dose of 25 mL/kg to a human being is 2.77 mL/kg. The
clinical dosage of KLT used in China is 200 mL/person
(70 kg), which is approximately 2.86 mL/kg.
Clinical applications show that KLT can improve im-
mune function, reduce chemotherapy toxicity [5], and
relieve cancer pain, thus improving the quality of life of
patients [2]. In the present study, mice treated with KLT
for 21 days showed no symptoms of physical discomfort,
and no significant differences were observed in average
body weight of the mice among the groups (P > 0.05).
This suggests that KLT did not produce significant non-
tumor toxicity in tumor-bearing mice.
Cell and animal experiments show that KLT can ac-
tivate some pro-apoptotic factors and block the tumor
cell cycle, further leading to tumor cell apoptosis [7,8].
TUNEL assays showed that the apoptosis indexes in the
KLT-treated groups were 9.16 ± 4.87%, 19.76 ± 8.44%, and28.43 ± 10.59%, for 6.25, 12.5, and 25 mg/kg, respectively.
These indexes were significantly higher than those in the
control group (P < 0.05). Therefore, KLT administration
inhibited PANC-1 xenograft tumor growth via induction
of tumor cell apoptosis. Similarly, Ye et al. found that the
apoptosis index was 55 ± 8% after liver cancer xenografts
were treated with KLT for 15 days [17].
The PI3K/Akt/mTOR pathway is very important in the
development of cancers, and plays a key role in cellular
functions including metabolism, survival, proliferation, ad-
hesion, migration, and invasion [18]. Phosphatidylinositol3-
kinases are a family of enzymes that phosphorylate
phosphatidylinositol. Phosphatidylinositol 3,4,5-triphos-
phate is a messenger generated by PI3K, which activates
Akt. Akt controls protein synthesis and cell growth by the
phosphorylation of mTOR [18]. In the present study, the
expression levels of PI3K, Akt, and mTOR mRNA and
protein were unchanged (P > 0.05) in KLT-treated groups
compared with those in the control group. However, pAkt
and p-mTOR expression levels were significantly lower
than those in the control group (P < 0.05). Therefore, KLT
can inhibit PI3K/Akt/mTOR signaling via inhibiting Akt
and mTOR phosphoration, rather than by influencing Akt
and mTOR.
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KLT can inhibit proliferation and induce apoptosis in
human pancreatic cancer xenografts. In addition, KLT
can downregulate pAkt and p-mTOR expression to regu-
late PI3K/Akt/mTOR signaling, which may contribute to
the anti-proliferative and apoptosis-inducing properties of
KLT. Nevertheless, further investigation is essential to re-
veal the modulating effect of KLT on proteins downstream
of the PI3K/Akt/mTOR pathway.
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